HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 290/6/R1616    most recent 00615.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by de Cavanagh, E. M. V. Articles by Inserra, F. Search for Related Content PubMed PubMed Citation Articles by de Cavanagh, E. M. V. Articles by Inserra, F.

RENAL HEMODYNAMICS AND CARDIORENAL INTEGRATION

Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine

¹Physical-Chemistry Department, School of Pharmacy and Biochemistry, University of Buenos Aires; ²Laboratory of Experimental Medicine, Hospital Aleman, Buenos Aires, Argentina; ³Department of Physiology, Ponce School of Medicine, Ponce, Puerto Rico; and ⁴Laboratory of Experimental Nephrology, Institute of Cardiovascular Research, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina

Submitted 24 August 2005 ; accepted in final form 5 January 2006

Mitochondrial dysfunction is associated with cardiovascular damage; however, data on a possible association with kidney damage are scarce. Here, we aimed at investigating whether 1) kidney impairment is related to mitochondrial dysfunction; and 2) ANG II blockade, compared with Ca²⁺ channel blockade, can reverse potential mitochondrial changes in hypertension. Eight-week-old male spontaneously hypertensive rats (SHR) received water containing losartan (40 mg·kg^–1·day^–1, SHR+Los), amlodipine (3 mg·kg^–1·day^–1, SHR+Amlo), or no additions (SHR) for 6 mo. Wistar-Kyoto rats (WKY) were normotensive controls. Glomerular and tubulointerstitial damage, systolic blood pressure, and proteinuria were higher, and creatinine clearance was lower in SHR vs. SHR+Los and WKY. In SHR+Amlo, blood pressure was similar to WKY, kidney function was similar to SHR, and renal lesions were lower than in SHR, but higher than in SHR+Los. In kidney mitochondria from SHR and SHR+Amlo, membrane potential, nitric oxide synthase, manganese-superoxide dismutase and cytochrome oxidase activities, and uncoupling protein-2 content were lower than in SHR+Los and WKY. In SHR and SHR+Amlo, mitochondrial H₂O₂ production was higher than in SHR+Los and WKY. Renal glutathione content was lower in SHR+Amlo relative to SHR, SHR+Los, and WKY. In SHR and SHR+Amlo, glutathione was relatively more oxidized than in SHR+Los and WKY. Tubulointerstitial -smooth muscle actin labeling was inversely related to manganese-superoxide dismutase activity and uncoupling protein-2 content. These findings suggest that oxidant stress is associated with renal mitochondrial dysfunction in SHR. The mitochondrial-antioxidant actions of losartan may be an additional or alternative way to explain some of the beneficial effects of AT₁-receptor antagonists.

kidney disease; nitric oxide; mitochondria; oxidative stress; hypertension

This article has been cited by other articles:

				A. K. Doughan, D. G. Harrison, and S. I. Dikalov Molecular Mechanisms of Angiotensin II-Mediated Mitochondrial Dysfunction: Linking Mitochondrial Oxidative Damage and Vascular Endothelial Dysfunction Circ. Res., February 29, 2008; 102(4): 488 - 496. [Abstract] [Full Text] [PDF]

				E. M. V. de Cavanagh, L. Ferder, J. E. Toblli, B. Piotrkowski, I. Stella, C. G. Fraga, and F. Inserra Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H456 - H465. [Abstract] [Full Text] [PDF]

				B. Piotrkowski, C. G. Fraga, and E. M. V. de Cavanagh Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1494 - R1501. [Abstract] [Full Text] [PDF]